25 April 2017 - Patients with lung cancer say they urgently need better-funded treatments for the disease, including Keytruda.

Medsafe has just approved the immunotherapy drug as a first treatment for some lung cancer patients, raising pressure for it to be funded.

Lung cancer is diagnosed in about 2200 New Zealanders a year and more than 1600 people die from it each year.

Read Radio New Zealand article